Dr. Kevin Flaherty, MD, FCCP answers common questions related to the newly approved treatments for IPF.

 
 p2p-icon(small)  

1. The primary efficacy results for pirfenidone and nintedanib seem to be quite close. What are the main safety considerations for each drug and how do these guide the choice for an individual patient?

Play


p2p-icon(small)  

2. What are the major considerations for adding pirfenidone or nintedanib to multiple medications that many of my patients are already on?

Play


p2p-icon(small)  

3. How will the recent drug approvals change the role of ILD centers?

Play


p2p-icon(small)  

4. Some of my patients have received other medications for IPF. If they are stable on NAC or corticosteroids should I switch to one of the newly-approved drugs?

Play


p2p-icon(small)  

5. How do the drug approvals impact lung transplant decisions?

Play


p2p-icon(small)  

6. Should we prescribe nintedanib or pirfenidone for patients with advanced IPF?

Play

Access other Therapeutic Areas: